{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-024187","form_type":"8-K","ticker":"TERN","cik":"0001831363","company_name":"Terns Pharmaceuticals, Inc.","filed_at":"2025-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.146009+00:00","generated_at":"2026-05-26T09:25:09.126280+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Terns Pharmaceuticals appoints Robert Azelby to board; Carl Gordon resigns","bullets":["Robert Azelby appointed to Board as Class I director effective Feb 20, 2025, and joins Compensation Committee.","Carl Gordon resigned from Board effective Feb 20, 2025 after over seven years; departure not due to disagreement.","Azelby brings 25+ years biopharma experience including CEO roles at Eliem Therapeutics and Alder BioPharmaceuticals.","Azelby received option to purchase 90,000 shares vesting over three years under non-employee director compensation plan.","Company highlights TERN-701 for chronic myeloid leukemia and obesity programs approaching clinical readouts."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-024187","json":"https://secwatch.observer/filing/0000950170-25-024187.json","markdown":"https://secwatch.observer/filing/0000950170-25-024187.md","text":"https://secwatch.observer/filing/0000950170-25-024187.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831363/000095017025024187/0000950170-25-024187-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831363/000095017025024187/tern-20250220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T09:25:09.126280+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7ea0624059","claim":"Carl Gordon resigned as Director at Terns Pharmaceuticals, Inc..","evidence_excerpt":"On February 20, 2025, Carl Gordon notified Terns Pharmaceuticals, Inc. (the “Company”) of his resignation from the Company’s Board of Directors (the “Board”), effective as of February 20, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831363/000095017025024187/0000950170-25-024187-index.htm","confidence":0.95},{"claim_id":"c96272df14","claim":"Robert Azelby was appointed as Director at Terns Pharmaceuticals, Inc..","evidence_excerpt":"On February 20, 2025, the Board appointed and elected Robert Azelby as a member of the Board, effective as of February 20, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831363/000095017025024187/0000950170-25-024187-index.htm","confidence":0.95}],"comparable_filings":[{"accession":"0001527166-26-000030","ticker":"CG","company_name":"Carlyle Group Inc.","filed_at":"2026-06-01T12:00:39+00:00","headline":"Carlyle appoints Kate Heinzelman as General Counsel; Jeff Ferguson to be Senior Advisor","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 7.01, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001527166-26-000030","json":"https://secwatch.observer/filing/0001527166-26-000030.json","markdown":"https://secwatch.observer/filing/0001527166-26-000030.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527166/000152716626000030/0001527166-26-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527166/000152716626000030/cg-20260601.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On February 20, 2025, Carl Gordon notified Terns Pharmaceuticals, Inc. (the “Company”) of his resignation from the Company’s Board of Directors (the “Board”), effective as of February 20, 2025.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1831363/000095017025024187/0000950170-25-024187-index.htm","comparable_excerpt":"Mr. Ferguson will become a Senior Advisor to Carlyle","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1527166/000152716626000030/0001527166-26-000030-index.htm"}},{"accession":"0001628280-26-038847","ticker":"HSY","company_name":"HERSHEY CO","filed_at":"2026-05-28T20:26:39+00:00","headline":"Hershey names Mitchell Arends as Chief Supply Chain Officer; Jason Reiman to retire after 30 years","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 7.01, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-038847","json":"https://secwatch.observer/filing/0001628280-26-038847.json","markdown":"https://secwatch.observer/filing/0001628280-26-038847.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/47111/000162828026038847/0001628280-26-038847-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/47111/000162828026038847/hsy-20260528.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On February 20, 2025, Carl Gordon notified Terns Pharmaceuticals, Inc. (the “Company”) of his resignation from the Company’s Board of Directors (the “Board”), effective as of February 20, 2025.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1831363/000095017025024187/0000950170-25-024187-index.htm","comparable_excerpt":"Mr. Reiman will step down from his current role on June 22, 2026, and will remain with the Company as Senior Vice President, Supply Chain Modernization to assist with the transition of his responsibilities until his retirement.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/47111/000162828026038847/0001628280-26-038847-index.htm"}},{"accession":"0001193125-26-245166","ticker":"FBIZ","company_name":"FIRST BUSINESS FINANCIAL SERVICES, INC.","filed_at":"2026-05-28T20:02:01+00:00","headline":"Scott M. Ferris appointed to FBIZ Board, effective June 1, 2026","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 7.01, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-245166","json":"https://secwatch.observer/filing/0001193125-26-245166.json","markdown":"https://secwatch.observer/filing/0001193125-26-245166.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1521951/000119312526245166/0001193125-26-245166-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1521951/000119312526245166/fbiz-20260522.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On February 20, 2025, Carl Gordon notified Terns Pharmaceuticals, Inc. (the “Company”) of his resignation from the Company’s Board of Directors (the “Board”), effective as of February 20, 2025.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1831363/000095017025024187/0000950170-25-024187-index.htm","comparable_excerpt":"appointed Mr. Scott M. Ferris as a Class III Director to fill the vacancy created by this increase.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1521951/000119312526245166/0001193125-26-245166-index.htm"}},{"accession":"0001628280-26-038632","ticker":"WDC","company_name":"WESTERN DIGITAL CORP","filed_at":"2026-05-28T13:08:27+00:00","headline":"Western Digital appoints Manuvir Das, former NVIDIA executive, to board","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.45,"calibrated_materiality_score":0.45,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 7.01, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-038632","json":"https://secwatch.observer/filing/0001628280-26-038632.json","markdown":"https://secwatch.observer/filing/0001628280-26-038632.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/106040/000162828026038632/0001628280-26-038632-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/106040/000162828026038632/wdc-20260526.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On February 20, 2025, Carl Gordon notified Terns Pharmaceuticals, Inc. (the “Company”) of his resignation from the Company’s Board of Directors (the “Board”), effective as of February 20, 2025.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1831363/000095017025024187/0000950170-25-024187-index.htm","comparable_excerpt":"On May 26, 2026, the Board of Directors (the “Board”) of Western Digital Corporation (the “Company”) unanimously appointed Manuvir Das to serve as a member of the Board","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/106040/000162828026038632/0001628280-26-038632-index.htm"}},{"accession":"0001193125-26-242975","ticker":"FVR","company_name":"FrontView REIT, Inc.","filed_at":"2026-05-28T11:05:16+00:00","headline":"FrontView REIT appoints Welltower Co-President and CFO Tim McHugh to board as independent director","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 7.01, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-242975","json":"https://secwatch.observer/filing/0001193125-26-242975.json","markdown":"https://secwatch.observer/filing/0001193125-26-242975.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1988494/000119312526242975/0001193125-26-242975-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1988494/000119312526242975/fvr-20260528.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On February 20, 2025, Carl Gordon notified Terns Pharmaceuticals, Inc. (the “Company”) of his resignation from the Company’s Board of Directors (the “Board”), effective as of February 20, 2025.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1831363/000095017025024187/0000950170-25-024187-index.htm","comparable_excerpt":"On May 28, 2026, the board of directors (the “Board”) of FrontView REIT, Inc. (the “Company”) elected Tim McHugh to serve as a director of the Company, effective May 28, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1988494/000119312526242975/0001193125-26-242975-index.htm"}},{"accession":"0001850902-26-000011","ticker":"TKNO","company_name":"Alpha Teknova, Inc.","filed_at":"2026-06-01T21:22:10+00:00","headline":"Alpha Teknova director Irene Davis to retire; board reduced from 8 to 7; shareholder votes approved nominees and auditor","event_type":"leadership","sec_items":["5.02","5.07","9.01"],"materiality_score":0.4,"calibrated_materiality_score":0.4,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001850902-26-000011","json":"https://secwatch.observer/filing/0001850902-26-000011.json","markdown":"https://secwatch.observer/filing/0001850902-26-000011.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850902/000185090226000011/0001850902-26-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850902/000185090226000011/tkno-20260527.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On February 20, 2025, Carl Gordon notified Terns Pharmaceuticals, Inc. (the “Company”) of his resignation from the Company’s Board of Directors (the “Board”), effective as of February 20, 2025.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1831363/000095017025024187/0000950170-25-024187-index.htm","comparable_excerpt":"On May 27, 2026, Irene Davis, a member of the Board of Directors (the “Board”) of Alpha Teknova, Inc. (the “Company”) and a member of the Nominating and Corporate Governance Committee, notified the Company of her intention not to stand for re-election to the Board at the Company’s 2026 Annual Meeting of Stockholders (the “Meeting”) and to retire from the Board and all committees thereof, effective upon the date of the Meeting.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1850902/000185090226000011/0001850902-26-000011-index.htm"}},{"accession":"0001477932-26-003559","ticker":"JOB","company_name":"GEE Group Inc.","filed_at":"2026-06-01T20:47:44+00:00","headline":"Darla Moore resigns from GEE Group board effective June 1, 2026, due to other commitments","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.35,"calibrated_materiality_score":0.35,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-26-003559","json":"https://secwatch.observer/filing/0001477932-26-003559.json","markdown":"https://secwatch.observer/filing/0001477932-26-003559.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/40570/000147793226003559/0001477932-26-003559-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/40570/000147793226003559/job_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On February 20, 2025, Carl Gordon notified Terns Pharmaceuticals, Inc. (the “Company”) of his resignation from the Company’s Board of Directors (the “Board”), effective as of February 20, 2025.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1831363/000095017025024187/0000950170-25-024187-index.htm","comparable_excerpt":"On June 1, 2026, GEE Group Inc. (the “Company”) (NYSE American: JOB) issued a press release announcing that Ms. Darla Moore, has resigned as a member of the Board of Directors (the “Board”) and from all committees of the Company’s Board effective June 1, 2026, due to the time requirements necessary for her existing and new business commitments.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/40570/000147793226003559/0001477932-26-003559-index.htm"}},{"accession":"0001534969-26-000028","ticker":"SERA","company_name":"SERA PROGNOSTICS, INC.","filed_at":"2026-06-01T20:44:21+00:00","headline":"Sera Prognostics director Jeff Elliott resigns ahead of annual meeting","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.3,"calibrated_materiality_score":0.3,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001534969-26-000028","json":"https://secwatch.observer/filing/0001534969-26-000028.json","markdown":"https://secwatch.observer/filing/0001534969-26-000028.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534969/000153496926000028/0001534969-26-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534969/000153496926000028/sera-20260526.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On February 20, 2025, Carl Gordon notified Terns Pharmaceuticals, Inc. (the “Company”) of his resignation from the Company’s Board of Directors (the “Board”), effective as of February 20, 2025.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1831363/000095017025024187/0000950170-25-024187-index.htm","comparable_excerpt":"Jeffrey T. Elliott, a member of the Board of Directors (the “Board”) of Sera Prognostics, Inc. (the “Company”), notified the Company of his decision to resign from the Board effective as of June 4, 2026","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1534969/000153496926000028/0001534969-26-000028-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}